Department of Nuclear Medicine, University of Medicine and Pharmacy Carol Davila, .
Department of Nuclear Medicine, University Emergency Central Military Hospital, .
Nucl Med Commun. 2024 Aug 1;45(8):651-657. doi: 10.1097/MNM.0000000000001863. Epub 2024 May 17.
Portal vein thrombosis, a relatively frequent complication associated with hepatocellular carcinoma (HCC) and liver cirrhosis, is recognized as a significant global health concern. This is mainly due to these conditions' high prevalence and potentially severe outcomes. The aim of our study was to conduct a comprehensive literature review to evaluate the efficacy, accuracy, and clinical implications of 18F-FDG PET-CT in diagnosing and managing portal vein tumor thrombosis (PVTT) in patients with HCC. HCC, which accounts for 80% of liver malignancies, ranks as the fourth most prevalent cancer globally and is a significant contributor to cancer-related mortality. The majority of HCC patients are diagnosed at an advanced stage, leading to a deterioration in patient outcomes. Involvement of the portal vein is also a significant negative factor. This review analyzes the application of 18F-FDG PET-CT in the detection and management of PVTT in patients with HCC, with an emphasis on the importance of the maximum standardized uptake value as an essential diagnostic and prognostic marker. 18F-FDG PET-CT is invaluable for detecting recurrence and guiding management strategies, particularly in patients with high-grade HCC, and plays a pivotal role in differentiating malignant portal vein thrombi from their benign counterparts.
门静脉血栓形成是与肝细胞癌（HCC）和肝硬化相关的一种相对常见的并发症，被认为是一个重大的全球健康问题。这主要是由于这些疾病的高患病率和潜在的严重后果。我们的研究旨在进行全面的文献综述，以评估 18F-FDG PET-CT 在诊断和管理 HCC 患者门静脉肿瘤血栓形成（PVTT）中的疗效、准确性和临床意义。HCC 占肝脏恶性肿瘤的 80%，是全球第四大常见癌症，也是癌症相关死亡的主要原因。大多数 HCC 患者在晚期被诊断出来，导致患者预后恶化。门静脉受累也是一个重要的负面因素。本综述分析了 18F-FDG PET-CT 在 HCC 患者 PVTT 检测和管理中的应用，重点强调了最大标准化摄取值作为重要的诊断和预后标志物的重要性。18F-FDG PET-CT 对于检测复发和指导管理策略非常有价值，特别是对于高级别 HCC 患者，并且在区分恶性门静脉血栓和良性门静脉血栓方面发挥着关键作用。
